NKTRNektar Therapeutics

CSNasdaq (XNAS)·USD

Identity

Security key: 19202
Ticker: NKTR
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1994-05-03
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: NKTR

Detail

Enriched 2026-08-14 20:47

Market cap: $2,568,752,012.96
Shares outstanding (class): 33,786,032
Shares outstanding (weighted): 33,786,032
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 63
Location: SAN FRANCISCO, CA
Homepage: https://www.nektar.com
Description: Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Market cap and share counts drift.

Funds holding this security

33 funds · 34 positions · $137.23M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$61.56M	0.00%	855,600 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$22.51M	0.03%	312,805 NS	FIGI
Invesco Main Street Small Cap Fund AIM Growth Series (Invesco Growth Series)	—	$13.09M	0.59%	181,904 NS	FIGI
Invesco V.I. Main Street Small Cap Fund AIM Variable Insurance Funds (Invesco Varia…	—	$6.94M	0.59%	96,504 NS	FIGI
DWS Small Cap Core Fund DEUTSCHE DWS INVESTMENT TRUST	—	$6.48M	0.62%	90,000 NS	FIGI
State Street(R) SPDR(R) S&P(R) Pharmaceuticals … SPDR SERIES TRUST	XPH	$5.79M	1.88%	80,506 NS	FIGI
iShares U.S. Pharmaceuticals ETF iShares Trust	IHE	$5.63M	0.56%	78,204 NS	FIGI
MassMutual Small Cap Opportunities Fund MASSMUTUAL PREMIER FUNDS	—	$3.02M	0.59%	42,037 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$2.74M	0.00%	38,090 NS	FIGI
1290 VT Micro Cap Portfolio EQ Advisors Trust	—	$1.47M	0.84%	20,366 NS	FIGI
Nomura Healthcare Fund Delaware Group Equity Funds IV	—	$1.23M	0.18%	17,092 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$1.10M	0.00%	15,256 NS	FIGI
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX… VANGUARD INSTITUTIONAL INDEX FUNDS	—	$928.9K	0.00%	12,911 NS	FIGI
MML VIP Invesco Small Cap Equity Fund MML Series Investment Fund II	—	$735.4K	0.59%	10,221 NS	FIGI
Inception Portfolio MORGAN STANLEY INSTITUTIONAL FUND INC	—	$646.3K	0.27%	8,982 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERNKTR
FIGI_COMPOSITEBBG000BHCYJ1
FIGI_SHARE_CLASSBBG001S7RDK1
CIK0000906709
ISINUS6402683063
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Nektar Therapeutics is a biopharmaceutical company developing drugs, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.